Previous 10 |
AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive...
EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September...
EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees. The ...
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executiv...
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...